Ilaria Attili

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT.

Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 23, 2026

Radiogenomic approach combining CT-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced NSCLC.

Radiogenomic approach combining CT-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced NSCLC.

Journal: The journal of liquid biopsy

Published: February 21, 2026

Epidermal Growth Factor Receptor (EGFR) atypical mutations in Non-Small-Cell Lung Cancer (NSCLC): 'where the streets have no name'.

Epidermal Growth Factor Receptor (EGFR) atypical mutations in Non-Small-Cell Lung Cancer (NSCLC): 'where the streets have no name'.

Journal: Critical reviews in oncology/hematology

Published: February 03, 2026

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.

Journal: Critical reviews in oncology/hematology

Published: February 03, 2026

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Journal: The oncologist

Published: September 19, 2025

Actionable driver gene alterations in early-stage non-small cell lung cancer: a review.

Actionable driver gene alterations in early-stage non-small cell lung cancer: a review.

Journal: Therapeutic advances in medical oncology

Published: September 01, 2025

Optimizing management of cutaneous toxicities from amivantamab in first-line non-small cell lung cancer: A clinical perspective.

Optimizing management of cutaneous toxicities from amivantamab in first-line non-small cell lung cancer: A clinical perspective.

Journal: Critical reviews in oncology/hematology

Published: June 18, 2025

Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer.

Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer.

Journal: Genes

Published: June 03, 2025

Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.

Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.

Journal: Clinical lung cancer

Published: May 16, 2025

HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the Top.

HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the Top.

Journal: Molecules (Basel, Switzerland)

Published: May 06, 2025

Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List.

Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List.

Journal: Cancers

Published: April 30, 2025

Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions.

Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions.

Journal: Cancer treatment reviews

Published: March 14, 2025

Showing 1-12 of 74

Last Updated: 09/26/2026